Jiangsu Cowin Biotech Co. Ltd. A
Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and pr… Read more
Jiangsu Cowin Biotech Co. Ltd. A - Asset Resilience Ratio
Jiangsu Cowin Biotech Co. Ltd. A (688426) has an Asset Resilience Ratio of 29.77% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Jiangsu Cowin Biotech Co. Ltd. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Jiangsu Cowin Biotech Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥468.74 Million | 29.77% |
| Total Liquid Assets | CN¥468.74 Million | 29.77% |
Asset Resilience Insights
- Very High Liquidity: Jiangsu Cowin Biotech Co. Ltd. A maintains exceptional liquid asset reserves at 29.77% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jiangsu Cowin Biotech Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Jiangsu Cowin Biotech Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Jiangsu Cowin Biotech Co. Ltd. A (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Jiangsu Cowin Biotech Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 25.77% | CN¥417.04 Million | CN¥1.62 Billion | -4.15pp |
| 2023-12-31 | 29.92% | CN¥545.28 Million | CN¥1.82 Billion | +9.33pp |
| 2022-12-31 | 20.59% | CN¥402.59 Million | CN¥1.96 Billion | -15.39pp |
| 2021-12-31 | 35.98% | CN¥233.42 Million | CN¥648.77 Million | -28.31pp |
| 2020-12-31 | 64.29% | CN¥303.17 Million | CN¥471.60 Million | -- |